CXCL12-G801A Polymorphism Modulates Risk of Colorectal Cancer in Taiwan

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2014 Feb 1

PMID 24482642

Citations 12

Authors

Ming-Der Shi

Jing-Hsien Chen

Hsin-Te Sung

Jung-Shin Lee

Li-Yu Tsai

Hui-Hsuan Lin

Affiliations

Soon will be listed here.

Abstract

Introduction: The chemokine CXCL12, designated stromal cell-derived factor-1 (SDF-1), plays a significant role in many cancer metastases. Previous studies have shown that CXCL12-G801A, a single nucleotide polymorphism (SNP) in the 3' untranslated region, correlates with breast and lung cancer in Iran. The aim of this study was to evaluate the association of the gene variant CXCL12-G801A with colorectal cancer (CRC) in a Taiwanese cohort.

Material And Methods: In this study, we used a denaturing high performance liquid chromatography (DHPLC) method to analyze the frequencies of CXCL12-G801A polymorphic variants between CRC patients (n = 258) and healthy controls (n = 300) in Taiwan.

Results: The SNP distribution was higher in CRC patients with TNM stage II (117/258) than healthy controls (52/300). We observed a significant increase in the G/A plus A/A genotype of the CXCL12-G801A polymorphism in CRC patients (45.35%) compared with healthy controls (17.33%). The analysis of allelic frequencies in both groups revealed that CRC patients have a higher frequency of A allele (23.45%) than healthy controls (8.67%). Furthermore, among older CRC patients, the frequency of the CXCL12-G801A genotype was significantly increased (p = 0.0148).

Conclusions: Our observations suggest that the CXCL12-G801A genotype may be associated with some clinical manifestations in CRC patients in Taiwan.

Citing Articles

Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case-control study in China.

Zhao D, Yu X, Huang H, Zou S, Zhu P, Lin Y Front Oncol. 2024; 14:1475979.

PMID: 39703847 PMC: 11655334. DOI: 10.3389/fonc.2024.1475979.

Uncovering potential genes in colorectal cancer based on integrated and DNA methylation analysis in the gene expression omnibus database.

Wang G, Wang F, Meng Z, Wang N, Zhou C, Zhang J BMC Cancer. 2022; 22(1):138.

PMID: 35114976 PMC: 8815138. DOI: 10.1186/s12885-022-09185-0.

MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis.

Karimzadeh M, Zarin M, Ehtesham N, Khosravi S, Soosanabadi M, Mosallaei M Cancer Gene Ther. 2020; 27(10-11):739-753.

PMID: 32203060 DOI: 10.1038/s41417-020-0172-0.

MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis.

Gholami M, Larijani B, Sharifi F, Hasani-Ranjbar S, Taslimi R, Bastami M Cancer Med. 2019; 8(17):7477-7499.

PMID: 31637880 PMC: 6885874. DOI: 10.1002/cam4.2600.

The CXCL12 rs1801157 polymorphism and risk of colorectal cancer: a meta-analysis.

Xu K, Dai H, Wang S, Zhang J, Liu T Onco Targets Ther. 2018; 11:2445-2452.

PMID: 29760554 PMC: 5937488. DOI: 10.2147/OTT.S151514.

References

Winkler C, Modi W, Smith M, Nelson G, Wu X, Carrington M . Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort.... Science. 1998; 279(5349):389-93. DOI: 10.1126/science.279.5349.389. View

Potter J . Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999; 91(11):916-32. DOI: 10.1093/jnci/91.11.916. View

Dommange F, Cartron G, Espanel C, Gallay N, Domenech J, Benboubker L . CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J. 2006; 20(11):1913-5. DOI: 10.1096/fj.05-5667fje. View

Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte J . CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005; 310(1):117-30. DOI: 10.1016/j.yexcr.2005.07.006. View

Kuklin A, Munson K, Gjerde D, Haefele R, Taylor P . Detection of single-nucleotide polymorphisms with the WAVE DNA fragment analysis system. Genet Test. 1997; 1(3):201-6. DOI: 10.1089/gte.1997.1.201. View

Hidalgo-Pascual M, Galan J, Chaves-Conde M, Ramirez-Armengol J, Moreno C, Calvo E . Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer. Oncol Rep. 2007; 18(6):1583-7. DOI: 10.3892/or.18.6.1583. View

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Zlotnik A, Yoshie O . Chemokines: a new classification system and their role in immunity. Immunity. 2000; 12(2):121-7. DOI: 10.1016/s1074-7613(00)80165-x. View

Zeelenberg I, Ruuls-Van Stalle L, Roos E . The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003; 63(13):3833-9. View

10.

Dubois-Laforgue D, Hendel H, Caillat-Zucman S, Zagury J, Winkler C, Boitard C . A common stromal cell-derived factor-1 chemokine gene variant is associated with the early onset of type 1 diabetes. Diabetes. 2001; 50(5):1211-3. DOI: 10.2337/diabetes.50.5.1211. View

11.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya A, Suehiro Y . CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007; 13(17):5056-62. DOI: 10.1158/1078-0432.CCR-07-0859. View

12.

Whitlock E, Lin J, Liles E, Beil T, Fu R . Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149(9):638-58. DOI: 10.7326/0003-4819-149-9-200811040-00245. View

13.

Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling M . Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia. 2007; 9(10):862-70. PMC: 2040213. DOI: 10.1593/neo.07559. View

14.

Dimberg J, Hugander A, Lofgren S, Wagsater D . Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 2006; 19(1):11-5. View

15.

Bleul C, Fuhlbrigge R, Casasnovas J, Aiuti A, Springer T . A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996; 184(3):1101-9. PMC: 2192798. DOI: 10.1084/jem.184.3.1101. View

16.

Balkwill F . Chemokine biology in cancer. Semin Immunol. 2002; 15(1):49-55. DOI: 10.1016/s1044-5323(02)00127-6. View

17.

Spiegelman J, Mindrinos M, Oefner P . High-accuracy DNA sequence variation screening by DHPLC. Biotechniques. 2000; 29(5):1084-90, 1092. DOI: 10.2144/00295rr04. View

18.

Kuklin A, Davis A, Hecker K, Gjerde D, Taylor P . A novel technique for rapid automated genotyping of DNA polymorphisms in the mouse. Mol Cell Probes. 1999; 13(3):239-42. DOI: 10.1006/mcpr.1999.0239. View

19.

Nanki T, Lipsky P . Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol. 2000; 164(10):5010-4. DOI: 10.4049/jimmunol.164.10.5010. View

20.

Kim J, Takeuchi H, Lam S, Turner R, Wang H, Kuo C . Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005; 23(12):2744-53. DOI: 10.1200/JCO.2005.07.078. View